Table 1.
Clinical characteristics of IBD patients: EBV-DNA positive and EBV-DNA negative in blood, EBER-1 positive and EBER-1 negative in intestinal mucosa
| EBV-DNA in blood |
EBER-1 intestinal mucosa |
|||||
|---|---|---|---|---|---|---|
| + (n=48) | − (n=520) | P | + (n=27) | − (n=21) | P | |
| Mean age (mean±SD) (years) | 35.11±15.83 | 47.56±17.91 | <0.001 | 48.89±17.67 | 44.90±17.81 | 0.500 |
| Sex (male/female), n | 37/11 | 275/245 | 0.001 | 19/8 | 18/3 | 0.185 |
| UC/CD, n | 28/20 | 230/290 | 0.060 | 19/8 | 9/12 | 0.055 |
| Fever, n (%) | 25 (52.1%) | 180 (24.6%) | 0.012 | 15 (55.6%) | 10 (47.6%) | 0.586 |
| Liver and spleen enlargement or lymphadenectasis, n (%) | 4 (8.3%) | 2 (0.4%) | <0.001 | 2 (7.4%) | 3 (14.3%) | 0.439 |
| Influenza-like symptoms, n (%) | 7 (14.6%) | 10 (1.9%) | <0.001 | 5 (18.5%) | 3 (14.3%) | 0.696 |
| Clinical disease activities*, n (%) | ||||||
| Mild | 0 (0.0%) | 0 (0.0%) | - | 0 (0.0%) | 0 (0.0%) | - |
| Moderate | 15 (31.2%) | 240 (46.2%) | 0.047 | 9 (33.3%) | 6 (28.6%) | 0.724 |
| Severe | 33 (68.6%) | 280 (53.8%) | 0.047 | 18 (66.7%) | 15 (71.4%) | 0.724 |
| The degree of intestinal mucositis, n (%) | ||||||
| Mild | 1 (2.1%) | 10 (1.9%) | 0.939 | 0 (0.0%) | 1 (4.8%) | 0.263 |
| Moderate | 18 (37.5%) | 235 (45.2%) | 0.305 | 7 (25.9%) | 11 (52.4%) | 0.060 |
| Severe | 29 (60.4%) | 275 (52.9%) | 0.317 | 20 (74.1%) | 9 (42.6%) | 0.030 |
IBD, Inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; EBV, Epstein-Barr virus; EBER-1, Epstein-Barr virus-encoded small-RNA 1. *Clinical disease activities: the Mayo Clinic score for ulcerative colitis (UC), Crohn’s disease activity index for Crohn’s disease (CD)